Sofinnova Partners closed its Capital XI fund at €650 million (about $750 million), surpassing target and committing more capital to early‑stage biotech and medtech companies. Firm partners said the fund will back therapeutics and platform companies, provide longer‑run support through financing cycles, and offer operational guidance alongside capital. Sofinnova highlighted active investments across Europe and North America and emphasized its ability to follow winners through multiple financing rounds. The close reflects renewed LP appetite for life‑science venture opportunities driven by potential M&A exits and selective late‑stage de‑risking. This fundraising adds to a broader wave of fresh VC capital into European life sciences, reinforcing the region’s startup funding lanes and potentially accelerating translational activity across oncology, gene therapy, and platform biotech.